CHMP supports Boehringer's nintedanib for IPF

EMA's CHMP recommended marketing authorization of Ofev nintedanib from Boehringer Ingelheim GmbH (Ingelheim, Germany) for the treatment of idiopathic pulmonary fibrosis (IPF). The compound is under accelerated assessment in the EU.

In September, CHMP recommended approval of nintedanib plus docetaxel to treat locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) with adenocarcinoma histology after failure of first-line chemotherapy (see BioCentury Extra, Sept. 26). ...